Calliditas, formerly Pharmalink, is a specialty pharmaceutical company focused on developing high-value medical products for patients with significant unmet medical needs in niche indications. Calliditas is focused on the development and commercialization of its lead product candidate, Nefecon, which has successfully completed a Phase 2b clinical study as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications, and will investigate the development of these to provide new treatments for patients with unmet medical needs.
Calliditas at a glance
What they do: Develops Nefecon® – an orphan drug project in an advanced clinical phase designed to treat inflammatory kidney disease.
Founded in: 2004
Headquarters: Stockholm, Sweden